In this review, we present our most recent understanding of key biomolecular processes that underlie two motor neuron degenerative disorders, amyotrophic lateral sclerosis, and spinal muscular atrophy. We focus on the role of four multifunctional proteins involved in RNA metabolism (TDP-43, FUS, SMN, and Senataxin) that play a causal role in these diseases. Recent results have led to a novel scenario of intricate connections between these four proteins, bringing transcriptome homeostasis into the spotlight as a common theme in motor neuron degeneration. We review reported functional and physical interactions between these four proteins, highlighting their common association with nuclear bodies and small nuclear ribonucleoprotein particle biogenesis and function. We discuss how these interactions are turning out to be particularly relevant for the control of transcription and chromatin homeostasis, including the recent identification of an association between SMN and Senataxin required to ensure the resolution of DNA-RNA hybrid formation and proper termination by RNA polymerase II. These connections strongly support the existence of common pathways underlying the spinal muscular atrophy and amyotrophic lateral sclerosis phenotype. We also discuss the potential of genome-wide expression profiling, in particular RNA sequencing derived data, to contribute to unravelling the underlying mechanisms. We provide a review of publicly available datasets that have addressed both diseases using these approaches, and highlight the value of investing in crossdisease studies to promote our understanding of the pathways leading to neurodegeneration.
proteins related to RNA metabolism are relatively frequent (Cooper et al. 2009) . Examples of such 'RNA-related' disorders are spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS).
ALS, the most frequent MND, is mostly an adult onset disease with a predominance of sporadic (90%) over hereditary cases, and a relatively high population incidence of 1/20 000 individuals . Pathologically and clinically, ALS is defined by the degeneration of upper and lower motor neurons resulting in muscle weakness and atrophy (symptoms of lower motor neuron dysfunction), but also stiffness, spasticity, hyperreflexia, and pseudobulbar symptoms (upper motor neuron dysfunction). In 30-50% of ALS patients, cognitive symptoms are also observed upon neuropsychological testing.
Familial cases of ALS have been linked to mutations in at least a dozen genes, with a predominance of mutations occurring in C9ORF72 (linked to 40% of all familial cases), SOD1, FUS, and TARDBP . About 10% of the sporadic cases have been linked to mutations in the same genes, but the remainder are of unknown origin (Renton et al. 2014) . In almost all cases (with the exception of familial SOD1 and FUS mutations), the cellular pathology shows cytoplasmic aggregation of the TDP-43 protein, encoded by the TARDBP gene (Mackenzie et al. 2007) . These aggregates are characterized by abnormal modifications of TDP-43, including N-terminal truncation, hyperphosphorylation, and ubiquitination. Similar neuropathological characteristics also occur in some cases of frontotemporal dementia (FTD) (Mackenzie and Neumann 2016) . The identification of C9ORF72 as a common disease gene in ALS and FTD has led them to be currently considered as the ends of a spectrum of related disorders (Renton et al. 2014) . Although patients may present exclusively with MND or frontotemporal lobar degeneration, in up to 50% of cases there is comorbidity of both disorders (Robberecht and Philips 2013) .
The histopathological hallmark features of ALS are the selective loss of motor neurons and the presence of cytoplasmic aggregates of misfolded proteins. Such aggregates are found in most neurodegenerative disorders, including Parkinson's and Alzheimer's disease, where abnormal TDP-43 staining is also frequent (Amador-Ortiz et al. 2007; Arai et al. 2009 ). Whether protein aggregates induce or protect from toxicity remains an open question. For the a-synuclein and b-amyloid proteins that form inclusions in Parkinson's and Alzheimer's patients brains, respectively, it is most likely that oligomers of few molecules are more toxic than the insoluble protein aggregates (Haass and Selkoe 2007) . In contrast, TDP-43 aggregates have been suggested to be key players in disease pathology, sequestering proteins and/or RNA (Vanden Broeck et al. 2014) . However, TDP-43 aggregation is not required for neurodegeneration in several animal models (e.g., Iguchi et al. 2013) , questioning its relevance for ALS pathology. Notwithstanding, several lines of evidence suggest that defective removal of misfolded proteins by the ubiquitin-proteasome system, ER stress and autophagy may be implicated in the disease phenotype (Kanekura et al. 2009; Menzies et al. 2015) . ALS-causing mutations are also linked to changes in other cellular pathways like axonal and mitochondrial dysfunction, oxidative stress, metabolic disturbance, and apoptosis (reviewed by Chen et al. 2013) . Remarkably, a subgroup of ALScausative genes can be defined by their connection to RNA metabolic pathways (Table 1 ). In addition to the RNAbinding proteins (RBPs) TDP-43 and FUS (Rutherford et al. 2008; Sreedharan et al. 2008; Kwiatkowski et al. 2009; Vance et al. 2009 ) discussed above as causing both familial and sporadic ALS, a juvenile form of familial ALS (ALS4) is caused by dominant mutations in the SENTX gene, which encodes the DNA-RNA helicase Senataxin (Chen et al. 2004) . Interestingly, Senataxin is highly related to the immunoglobulin mu binding protein 2 (encoded by the IGHMBP2), associated to spinal muscular atrophy with respiratory distress type 1 (Grohmann et al. 2001) .
Other proteins linked to RNA metabolism implicated in ALS include angiogenin, involved in tRNA and rRNA biogenesis (Greenway et al. 2004) , Matrin 3 (Johnson et al. 2014) , and the RBPs hnRNPA1 and hnRNPA2B1 (Kim et al. 2013) (Table 1) . Although mutations in the MATR3 gene were originally described as causing an autosomal dominant myopathy (Senderek et al. 2009 ), later clinical re-evaluation of these patients supports the reclassification of their condition as slowly progressive ALS (Johnson et al. 2014) . Matrin 3 is a regulator of RNA processing (Salton et al. 2011; Coelho et al. 2015 ) that interacts directly with TDP-43, FUS, hnRNPA1, and hnRNPA2B1 (Ling et al. 2010; Hein et al. 2015) . Mutations in the later two proteins have been linked to both ALS and multisystem protein disorder (Kim et al. 2013) . These mutations occur within low-complexity prion-like domains that are intrinsically prone to aggregation and are common in other RBPs, including FUS, TDP-43, and Matrin 3, thereby suggesting an explanation for the existence of 'RBP-related' proteinopathies (Kim et al. 2013) . However, as mentioned above, several lines of evidence suggest that the formation of protein aggregates is not a requirement for MND.
Although the normal function of the protein encoded by the C9ORF72 gene remains unclear, several lines of evidence point to connections between the disease-causing mutation and RNA metabolism. Three hypotheses are currently under debate to explain how the intronic hexanucleotide expansion repeat in the C9ORF72 gene reported in 2011 (DeJesusHernandez et al. 2011; Renton et al. 2011) leads to MND. These include loss-of-function of the C9orf72 protein, a toxic RNA gain-of-function and a toxic effect from di-peptide repeat molecules synthesized by aberrant translation of repeat-containing RNAs (recently reviewed by Gitler and Tsuiji 2016) . The RNA-dependent toxicity has been proposed to occur through sequestration of RBPs, including TDP-43, potentially disrupting RNA processing (CooperKnock et al. 2012; Lee et al. 2013) . The di-peptide repeat proteins formed by repeat-associated non-AUG translation of mutant transcripts have also been shown to interfere with pre-mRNA splicing and ribosomal RNA biogenesis (Kwon et al. 2014) . Interestingly, both repeat RNAs and di-peptide repeat proteins have independently been implicated in the disruption of nucleo-cytoplasmic trafficking (Freibaum et al. 2015; Jovi ci c et al. 2015; Zhang et al. 2015) .
As mentioned above, C9ORF72 mutations are the prevailing cause of both ALS and FTD. Several studies report a possible association with other neurodegenerative disorders (Liu et al. 2014) . However, a recent survey of SMA patients suggests that C9ORF72 variants do not constitute a causal or predisposing factor for this MND (Al ıas et al. 2014) .
Spinal muscular atrophies are a heterogeneous group of neurodegenerative disorders characterized by the degeneration of anterior horn cells of the spinal cord, leading to progressive symmetric muscle weakness and atrophy (Simic 2008) . We refer to the most common form of this group of disorders as SMA (reviewed by Monani 2005) . SMA is caused by hereditary recessive mutations in the survival of motor neuron 1 (SMN1) gene, located in the small arm of chromosome 5 (Lefebvre et al. 1995) . Although rare compared to ALS, SMA is the second most common autosomal recessive disorder after cystic fibrosis, with a pan-ethnic carrier frequency of 1 : 54 (Sugarman et al. 2012) . It is also the most common cause of hereditary childhood death, usually leading to death within the first year of life (Monani 2005) . However, juvenile and adult onset forms also exist. In fact, there are four distinct forms of the disease described: SMA1 (OMIM #253300), SMA2 (OMIM #253550), SMA3 (OMIM #253400), and SMA4 (OMIM #271150), clinically defined by an increase in the age of onset and a decrease in the severity of symptoms. These various forms of SMA are the consequence of the presence of varying copy numbers of a strong disease-modifying gene in the human genome: SMN2 (Taylor et al. 1998) . SMN2 appeared as the AD, autosomal dominant; ADSMA, autosomal dominant spinal muscular atrophy; AR, autosomal recessive; fALS, familial ALS; FTD, frontotemporal dementia; GEF, GDP/GTP exchange factor; Gly-rich LCD, glycine-rich low complexity domain; IHER, intronic hexanucleotide expansion repeat; MSP, multisystem proteinopathy; RBP, RNA-binding protein; mRNP, messenger ribonucleoprotein particle; snRNP, small nuclear ribonucleoprotein particle; RRM, RNA recognition motif; sALS, sporadic ALS.
consequence of an inverted duplication of a 500 kb region of the human chromosome 5 containing SMN1 and some of its neighboring genes (Lorson et al. 2010) . Compared to SMN1, this gene contains a single silent substitution in exon 7 that reduces the splicing efficiency, resulting in a reduced ability to support the synthesis of full length SMN protein Monani et al. 1999) . While in healthy individuals SMN2 is non-essential, the presence of two copies of this gene is required for viable birth in individuals with homozygous mutations in SMN1, and increased copy numbers correlate with decreased disease severity (Taylor et al. 1998) . SMA is the paradigm for 'RNA metabolism' associated diseases. As discussed in more detail in the next sections, the SMN protein, encoded by the disease-causing gene, is a critical component of the pathway required for the biogenesis of the splicing machinery. In all animal and yeast models tested so far, SMN is required for cell survival. In humans, the presence of the SMN2 gene supports just enough SMN protein synthesis to allow for embryonic and fetal development, with conspicuous symptoms usually appearing within a few weeks after birth in SMA1 patients. While the primary pathology is neurodegeneration, it has become increasingly clear that other tissues are also affected, especially in severely affected patients (Shababi et al. 2013) . Although the reasons for the strong motor neuron phenotype in SMA remain elusive, the prevalence of 'RNA metabolism' among the primary functions of ALS-causing genes suggests a common theme in MND. Among rarer motor neuron diseases this connection is also observed, with reported mutations in IGHMBP2, EXOSC3 (part of the RNA exosome complex), GLE1 (involved in nuclear RNA export) and, strikingly, SETX (reviewed by Peeters et al. 2014) .
Recently, several publications have revealed strong molecular links between the four key SMA and ALS proteins involved in RNA metabolism, SMN, TDP-43, FUS, and Senataxin. This provides new support for the hypothesis of a shared pathomechanism linked to transcriptome homeostasis in MND, setting the stage for the present review.
Structure and mutant forms of TDP-43, FUS, SMN and Senataxin TDP-43, or TAR DNA-binding protein with 43 kDa, was originally identified by its ability to bind single-stranded (ss) DNA from the HIV promotor and inhibit its transcription (Ou et al. 1995) . TDP-43 has two RNA recognition motifs that determine a binding preference for (UG) 5 motifs, in addition to binding to TG sequences in ssDNA. It additionally features a C-terminal glycine-rich region that is typical of the heterogeneous nuclear ribonucleoparticle protein (hnRNP) family and is reported to function as a protein-protein interaction domain (Singh and Valc arcel 2005;  Fig. 1a ). As mentioned above, hyperphosphorylated TDP-43 was found to be a major component of intracellular inclusions in many cases of sporadic and familial ALS and FTLD (Neumann et al. 2006) . Numerous ALS-linked mutations in the TARDP gene have been reported, most of them dominant missense substitutions affecting the C-terminal domain (LagierTourenne et al. 2010) . However, it is presently unclear whether these mutations are a true gain-of-function or a lossof-function through dominant-negative effects (Vanden Broeck et al. 2014) .
Even though it is often referred to as an hnRNP protein, FUS belongs to the TET protein family, which includes the EWS transcriptional regulator and the TATA-binding protein-associated factor TAF15 (Tan and Manley 2009) . These three proteins share a similar structure characterized by an Nterminal QGSY-rich region, a highly conserved RNA recognition motifs, multiple RGG repeats, which are extensively dimethylated at arginine residues, and a C-terminal zinc finger motif. FUS additionally contains the glycine-rich region typical of hnRNPs (Fig. 1b) . FUS has been reported to bind a common GUGGU motif in RNA molecules (Lagier-Tourenne et al. 2012) , although it also seems to display DNA-binding activity, including binding to telomeric DNA through the motif (TTAGGG) 4 (Takahama et al. 2009 ). However, a more recent study profiling in vivo FUS RNA-binding sites failed to identify any clear binding motifs in 80% of the detected FUS targets (Nakaya et al. 2013 ). This suggests that FUS has a low sequence specificity in RNA binding. At least 30 ALS-causative mutations have been reported in the FUS gene. The majority of them are dominant missense mutations, clustered either along the glycine-rich region or in the final C-terminal 17 amino acids, which constitute the protein's nuclear localization signal (NLS) Fig. 1b) . Mutated FUS forms cytoplasmic aggregates in lower motor neurons of affected patients (Vance et al. 2009) . A recent study has further shown that the physiological role of FUS requires forming dynamic liquid-like compartments, in particular at sites of DNA damage (Patel et al. 2015) . Such compartments are more prone to aberrant liquid-to-solid phase transitions into aggregated states, which are accelerated by ALS-causing mutations. Although this work does not address the reason why aggregates seem to associate to disease states, it provides a detailed biophysical model for their formation based on specific protein characteristics.
In contrast to FUS and TDP-43, SMN does not belong to the RBP/hnRNP family, being characterized by the presence of a Tudor domain. The Tudor domain is a conserved sequence motif that mediates protein-protein interactions through the recognition of methylated arginine residues (Chen et al. 2011) . Specifically, the SMN Tudor domain has been shown to bind to RG-rich motifs commonly found in RBPs, depending on the symmetrical dimethylation of specific arginine residues. In addition, SMN presents two dimerization domains required for its function as an oligomeric complex and a YG box domain, commonly found in RBPs. Although the vast majority of SMA-causing mutations involve large deletions of the SMN gene, several missense mutations affecting the Tudor domain and the dimerization and YG box domains have been reported, highlighting the importance of these regions for the disease phenotype Fig. 1c) .
Finally, Senataxin belongs to the superfamily I of DNA-RNA helicases. It is a large, 302 kDa protein that contains a N-terminal protein-protein interaction domain and a C terminal domain composed of seven helicase motifs, followed by a NLS (Hashemi et al. 2006; Fig. 1d ). Three dominant missense substitutions, two in the N-terminal and one in the C-terminal helicase domain have been identified in type 4 ALS patients (Chen et al. 2004) . Strikingly, the ALScausing missense variant p.L389S was identified in a family suffering from autosomal dominant proximal spinal muscular atrophy, with more affected siblings presenting a second SETX missense mutation of unknown function (V891A) in trans (Rudnik-Sch€ oneborn et al. 2012). Moreover, homozygous missense mutations in the same protein domains linked to ALS are found in patients suffering from AOA2, which presents as a recessively inherited disorder (Moreira et al. 2004) . Thus, similar mutations in the SETX gene can lead to a variety of diseases with neuromuscular symptoms, likely influenced by the genetic background.
SMN, FUS, TDP-43, and STX are shuttling proteins with multiple functions in RNA processing
The functional diversity typically found within the world of 'RNA metabolism' proteins is well illustrated by the four RNA-associated proteins discussed in this review. All these proteins shuttle between the cytoplasm and the nucleus, participating in the regulation of multiple successive steps in the RNA biogenesis pathway.
At steady-state, FUS and TDP-43 accumulate predominantly in the nucleus where they control transcription, splicing and participate in microRNA biogenesis (reviewed by Lagier-Tourenne et al. 2010) . In neurons, these proteins also localize to RNA granules and regulate their transport to dendritic or axonal extensions. In addition, FUS and TDP-43 regulate the translation of target neuronal mRNAs (Belly et al. 2005; Vance et al. 2013 ). As mentioned above, defective subcellular distribution of these proteins is frequently observed in ALS (Neumann et al. 2006; Mackenzie et al. 2010) . For example, disease-associated mutations in FUS were shown to disrupt the normal nuclear localization of mutant proteins and to concomitantly lead to the cytoplasmic accumulation of pathological aggregates. This has raised the debate as to whether the associated MND results from nuclear depletion of FUS or rather a cytotoxic gain of function.
SMN is also a ubiquitous shuttling protein that localizes predominantly in the cytoplasm, with strong accumulation in nuclear structures termed Cajal bodies (CBs). To date, the main reported function of SMN has been as a chaperone for the assembly of U-rich small nuclear (sn) RNA-protein complexes termed UsnRNPs (B€ uhler et al., 1999) . Indeed, the SMN complex, formed by SMN homodimers, Gemins 2-8, and the Unrip protein, is responsible for the assembly of ribonucleoprotein complexes between the Sm and LSm proteins and UsnRNAs (Battle et al. 2006) . The UsnRNAs are specifically recognized and delivered to SMN-Gemin2 by Gemin5 (Yong et al. 2010) . This complex's assembly activity is responsible for generating the core cellular machinery involved in diverse RNA pathways, including pre-mRNA splicing (e.g., the major and minor UsnRNPs), histone mRNA 3 0 -end processing (the U7snRNP), and cytoplasmic mRNA decay (the LSm complex) (He and Parker 2000; Tisdale et al. 2013; Li et al. 2014) . The SMN complex may additionally be required for the assembly of small nucleolar (sno)RNPs involved in rRNA processing (Jones et al., 2001) , as well as in the assembly of a U1snRNA-TAF15 transcriptional complex (Jobert et al. 2009 ). Adding to these functions, SMN was shown to recognize methylation marks in histones (Sabra et al. 2013) and to interact with the axonal mRNA transport machinery, namely through direct association with actin-binding proteins and neuronal RBPs containing dimethylated RG domains (reviewed by Fallini et al. 2012a) .
Senataxin was originally named after its well-characterized yeast orthologue Sen1p, a large DEAxQ-box helicase involved in DNA repair and transcription termination. Early studies on the role of Senataxin in AOA2 cells suggested that it was involved in the DNA damage response, which was proposed to be the critical mechanism underlying neurodegeneration (Suraweera et al. 2007) . Later studies from the same group revealed that, just like yeast Sen1p, the vertebrate protein was involved in the regulation of transcription termination and splicing (Suraweera et al. 2009 ). Like SMN, FUS, and TDP-43, Senataxin has also been reported to be present in the cytoplasm, thereby suggesting that it may have additional cellular functions, in particular in neurons (Hashemi et al. 2006; Vantaggiato et al. 2011) .
In summary, these four proteins form a heterogeneous group of multifunctional regulators of RNA metabolism processes. The fact that FUS, TDP-43, SMN, and Senataxin are all ubiquitously expressed and participate in core cellular functions is one of the major puzzles regarding the tissue specific nature of their associated diseases. Among these functions, pre-mRNA splicing emerges as a common signature that has captured the interest of the research community, given its relevance for the expression of neuronal genes and critical role in establishing tissue specific gene expression patterns.
Defective splicing: a common mechanism underlying FUS, TDP-43, and SMN-dependent pathologies?
The discovery of ALS-causing mutations in FUS and TDP-43 lead to the hypothesis that these proteins might participate in the splicing of common targets critical for motorneuron function. Several labs have since performed systematic searches for these connections, with somewhat disappointing results (Lagier-Tourenne et al. 2012; Rogelj et al. 2012; Honda et al. 2014) . Taking advantage of the recent developments in RNA-seq methods, both the mapping of RNAbinding sites and the assessment of changes in splicing patterns in cells and tissues expressing mutant versions of FUS and TDP-43 have been explored (Table 2 ). In addition, global changes in gene expression have been characterized (see recent review by Lagier-Tourenne et al. 2010) . Results show that the RNA-binding profiles of FUS and TDP-43 and corresponding regulated splicing events are quite distinct (Polymenidou et al. 2011; Rogelj et al. 2012) . Nevertheless, global classification of the RNA targets of these proteins reveals an enrichment for genes relevant for neuronal function. This may just reflect the fact that neuronal genes tend to present more complex splicing patterns (Zheng and Black, 2013) . RNA-seq of mouse brain and spinal cord tissue after in vivo knock-down of FUS and TDP-43 revealed only a small subset of commonly affected genes (Lagier-Tourenne et al. 2012) . These genes were found to contain longer introns than the mouse genome average, suggesting that these proteins may be required for the processing of long pre-mRNAs. Increased interaction of FUS with long introns was reported independently and suggested to be linked to the need to suppress recognition of cryptic splicing sites (Rogelj et al. 2012) . More recent studies confirmed a role for TDP-43 in the splicing of long introns . Another study analyzing gene expression and splicing changes in mouse cortical neurons after shRNA depletion of TDP-43 and FUS identified two small sets of~50 transcripts commonly affected by both proteins at the gene expression level or at the splicing level (Honda et al. 2014) . Given the total number of genes affected by each protein individually, this overlap was only significant for genes showing global changes in expression, which may just reflect a common downstream response by neuronal cells. It remains totally unclear how TDP-43 and FUS knock-down lead to these changes. Of note, the degree of overlap between this study and the previous work by Lagier-Tourenne et al. (2012) was minimal.
The exploration of splicing defects in SMA has been a rather obvious pursuit since the discovery of the role of SMN in the biogenesis of small nuclear ribonucleoprotein particle (snRNP) complexes. Once again, the results obtained by different groups have revealed conflicting stories and failed so far to establish clear mechanistic connections between SMN levels, splicing aberrations and motor neuron degeneration. Several reports have provided convincing evidence that a decrease in SMN levels results in cell type specific changes in the snRNP repertoire (reviewed by Chari et al. 2009 ). However, although the relative abundance of different snRNPs changes, there is no reason to assume that the composition of spliceosomes assembled on pre-mRNAs is affected, in particular considering that these complexes remain very abundant in cells. Zhang and co-workers were the first to address the genome-wide impact of low SMN levels in splicing using exon arrays. They reported changes in the splicing patterns of roughly 10% of the expressed genes . Although this is far from a widespread defect as claimed by the authors, the nature of the observed changes and the fact that they occur preferentially in genes with large numbers of introns speaks in favor of a disruption of general splicing mechanisms. Thus, it was proposed that perturbations in the snRNP repertoire influence the efficiency, rate and fidelity of splicing . This view was supported by a study demonstrating an increased error rate in splice site pairing in cells from SMA patients (Fox-Walsh and Hertel 2009). Focusing on the fact the snRNA components of the minor spliceosome seem to be the most consistently affected by low SMN levels, Lotti and co-workers presented evidence that genes containing minor spliceosomal introns were specifically affected in different SMA models, proposing that this would disrupt a critical cellular pathway for neuronal development (Lotti et al. 2012) .
The relevance of splicing aberrations because of an altered snRNP repertoire has been called into question by two different types of data. First, two studies have described SMN mutations that uncouple snRNP biogenesis from the motor neuron phenotype (Carrel et al. 2006; Praveen et al. 2012) . In zebrafish, a truncated SMN protein expected to be non-functional in snRNP assembly was able to rescue motor axon defects, unlike the snRNP-assembly competent hSMN (A111G) mutant (Carrel et al. 2006) . However, a later study from the same authors showed that higher doses of hSMN (A111G) could in fact rescue the phenotype in both zebrafish and mice, in the presence of low levels of wt SMN (Workman et al. 2009 ). The impact of the truncation mutant in snRNP assembly and SMA mice was not evaluated because of technical difficulties. The observation that disruption of other central players of the snRNP assembly pathway can lead to motor phenotypes in mouse (Winkler et al. 2005) and fly (Borg et al. 2016 ) lends support to a role for this pathway in SMA, in line with experiments showing that the motor axon phenotype in SMN-deficient zebrafish embryos can be prevented by co-injection of purified UsnRNPs (Winkler et al. 2005) . However, the observation in Drosophila that the SMN T205I disease mutation generates a phenotype compatible with mild SMA without disrupting snRNP biogenesis or snRNA levels suggests that non-snRNP assembly functions of SMN may also play a critical role in the etiology of the disease, at least in this model organism (Praveen et al. 2012) . This is supported by a later study from the same lab reporting that three hypomorphic SMN missense mutants do not share the splicing profile changes common to SMN null and snRNP biogenesis mutants (Garcia et al. 2016) .
Second, the so-called widespread changes in splicing have been proposed to represent late features of the disease (B€ aumer et al. 2009 ), or an indirect consequence of delayed neuronal development (Garcia et al. 2013) . In fact, the analysis of splicing defects in early, asymptomatic stages in a mouse model of SMA revealed a very small number of cell-type-specific splicing changes that did not involve minor spliceosomal introns . These included altered splicing in a few genes involved in synaptogenesis, which the authors argue could be the basis for the disease phenotype. A striking parallel observation was the up-regulation of the mRNAs encoding the three subunits of the C1q protein complex. C1q is known to be involved in neurodegeneration and synaptic pruning during CNS development (Stevens et al. 2007 ). Interestingly, this complex has also been reported to be up-regulated in mouse models of ALS (Saxena et al. 2009 ). Although C1q up-regulation provides an interesting link between SMN levels and neurodegeneration, its change in expression is difficult to explain based on the splicing disruption hypothesis. Thus, many questions still remain unanswered regarding the primary changes in the motor neuron transcriptome that are triggered by mutations in SMA and ALS causal genes, and how they are connected to the disease phenotype. There is, however, an abundance of evidence supporting the existence of functional interactions between the molecular pathways underlying both disorders.
New connections between ALS and SMA
As discussed above, ALS and SMA are both characterized by a progressive degeneration of motor neurons in the anterior horns of the spinal cord. The classical presentation of ALS is that of a sporadic disorder with onset after the forth decade of life, but with a very heterogeneous clinical presentation, from site and age of onset, familial occurrence, type of motor neuron involvement, extent of extra-motor involvement and disease duration, among others (Swinnen and Robberecht 2014) .
In spite of a more consistent clinical presentation as a very severe, hereditary, early childhood disorder, SMA can overlap with the ALS spectrum of manifestations. Indeed, cases of late to adult onset of the disease are known, usually linked to the presence of extra copies of the SMN2 gene, as discussed above. Interestingly, several authors have reported SMN1 and SMN2 copy numbers as susceptibility factors for sporadic ALS in different populations (Veldink et al. 2005; Corcia et al. 2012 ; reviewed by Butchbach 2016) . Although there are some conflicting data, a recent study of a large cohort of ALS patients, coupled with a meta-analysis of previous data, reported SMN1 duplications as one of the highest known risk factors for sporadic ALS (Blauw et al. 2012) . The emerging genetic connections between the two diseases are further underscored by studies in cellular and animal models of ALS that report functional interactions with SMN. Indeed, over-expression of SMN was shown to rescue the axonal growth and branching-defects observed in FUS mutant neurons (Groen et al. 2013) . Increased SMN levels also improved neuromuscular function and motor neuron survival in mice with expression of a ALS-causing mutation in the SOD1 gene (Turner et al. 2014) . Finally, a very recent study shows that neuronal over-expression of human SMN delays symptom onset and prolongs survival in mice bearing the TDP-43 A315T mutation, by counter-acting both motor neuron degeneration and inflammatory glial cell activation (Perera et al. 2016) .
Taken together, these studies reveal the existence of shared mechanisms underlying ALS and SMA, which may actually extend to settings that appear unrelated to RNA metabolism, as is the case of SOD1 mutations. Such connections are beginning to be unraveled by both genetic and functional studies and, importantly, through the analysis of the protein interaction profiles of the disease-causing genes, as discussed next. Sun et al. 2015) . Data from high-throughput proteomic approaches to systematically map protein-protein interactions in different model organisms are publicly available and can be used to generate a relatively detailed view of the interactomes of these four proteins. We performed a systematic retrieval of the interactions for SMN, TDP-43, FUS, and Senataxin from different data resources and recovered a set of 136 proteins that interact simultaneously with at least two of them (Fig. 2) . This analysis revealed a highly interconnected network of interactions between the four proteins, which preserves around 20% of each individual interactome. Noteworthy, the analysis of functional gene ontology terms associated to this network showed nine highly enriched functional clusters linked to: (i) spliceosome assembly; (ii) translational elongation/ termination; (iii) RNA processing; (iv) ubiquitin-dependent protein degradation; (v) DNA repair; (vi) rRNA processing; (vii) transcription termination; (viii) microtubule-based movement, and (ix) cell death and apoptosis (Fig. 2) . These clusters highlight some expected connections, considering the current knowledge about SMA and ALS (such as spliceosome assembly, rRNA processing, or translation control). More interestingly, they foreshadow the most recent discoveries linking TDP-43, FUS, SMN, and Senataxin to specific aspects of gene expression regulation, including transcription termination and DNA repair, as discussed in the next sections.
Protein networks revealing links between SMN, TDP-43, FUS and Senataxin

A common cellular location for the four proteins: buddies in nuclear bodies
The finding that the SMN protein is involved in the assembly of UsnRNPs led to the early hypothesis that this process is affected in SMA (Liu et al. 1997) . Indeed, later biochemical studies showed that snRNP assembly is less efficient in cell lines with SMN down-regulation as well as in SMA patient cells (reviewed by Chari et al. 2009 ).
snRNP biogenesis is a complex process that begins with the RNA Polymerase II (Pol II)-dependent transcription of two types of RNAs: mRNAs coding for Sm core and snRNP specific proteins; and non-coding UsnRNAs (with the exception of the U6snRNA, transcribed by RNA Polymerase III). Both types of RNAs are exported to the cytoplasm, where the SMN complex helps to assemble snRNAs and Sm proteins into early snRNPs (Fig. 3) . snRNAs, however, accumulate first in a discrete nuclear structure, the Cajal body (CB), where they undergo several processing steps before moving to the cytoplasm (reviewed by Matera and Wang 2014) . After assembly in the cytoplasm, snRNPs are re-imported into the nucleus and targeted to CBs, where they are subject to further maturation steps before becoming active in splicing.
In spite of the absence of membranous compartments, the nucleus has a high degree of spatial organization. The nucleoli represent the most prominent and best-known example of a 'subnuclear' compartment. During the last decades, the existence of a plethora of such structures, often termed 'nuclear bodies', has become apparent. Among them are the CBs, gemini of Cajal bodies (or gems) and histone locus bodies (HLBs) (reviewed by Machyna et al. 2013) . CBs were first identified by Ram on y Cajal in CNS neurons. Decades later, CBs were also found in non-neuronal cells and referred to as coiled bodies (reviewed by Gall 2000) . During the last decades, CB function has been characterized in greater detail. It has been suggested that CBs represent the core of the three above mentioned nuclear bodies, which clearly seem to be functionally related. Indeed, CBs, gems and HLBs are surprisingly dynamic and depending on the cell type and metabolic state, they may or may not be visible or even seem to coalesce with each other into a single body (Machyna et al. 2013) . CBs are defined by the presence of the protein coilin and are primarily believed to represent way stations in the snRNP biogenesis pathway ( Fig. 3; reviewed Fig. 2 The FUS, TDP-43, SMN, and Senataxin interactome. Physical interactions for each protein were recovered from GeneMania, IntAct, Mentha and by manual curation of the literature (available as a supplementary data file). Interaction partners shared by at least two of these proteins are presented in the figure, corresponding to a total of 136 proteins. The network was generated using Cytoscape. Functional classification of the interaction network was performed using TopGo for functional enrichment and GeneTerm Linker for clustering of enriched GO terms (Aibar et al. 2015) . Proteins are color coded according to the corresponding functional cluster, as presented in the legend. Proteins that are part of more than one functional cluster have a thick node border and the color shown represents the functional clusters with the lower enrichment p-value.
by Matera and Wang 2014) . In addition, they contain several other proteins and RNAs involved in snRNP maturation and recycling after splicing, including the SMN complex. CBs have also been shown to associate with snRNA and histone gene clusters (Frey and Matera 1995) , and may contain histone processing and transcription factors, including the U7snRNA and NPAT. However, these proteins often appear to segregate to the related HLBs, which lack SMN and spliceosomal UsnRNPs (Nizami et al. 2010 ). Gems were originally described by the Dreyfuss lab as a distinct nuclear structure from CBs, containing only SMN complex components but not snRNPs (Liu and Dreyfuss 1996) . The function of gems remains presently unknown and they seem to coalesce with CBs, in particular in contexts of increased snRNP maturation (Liu and Dreyfuss 1996) . Notably, in motor neurons, gems, and CBs predominantly coincide in a single structure (Cioce and Lamond 2005) .
In agreement with a role for CBs and gems in snRNP biogenesis, the hallmark cellular phenotype of SMA is a disease severity-dependent reduction in their numbers (Feng et al. 2005) . Recently, several groups have reported that gems are also disrupted in ALS models, therefore establishing another striking connection between both diseases (reviewed by Cauchi 2014). Both TDP-43 and FUS were found to bind to SMN and accumulate in gems, and to be required for the maintenance of these structures (Yamazaki et al. 2012; Ishihara et al. 2013; Tsuiji et al. 2013) . TDP-43 has also been reported to be present in CBs, which likewise seem to be reduced in number in ALS spinal cord MNs (Ishihara et al. 2013) . The mouse homolog of FUS (Pigpen) was one of the first CB components to be identified, suggesting that FUS also has connections to this subcellular compartment (Cioce and Lamond 2005) . Moreover, the targeting of SMN to CBs and the assembly of gems were found to be disrupted in SOD1 mutant mice, thereby placing these structures at the core of the ALS phenotype (Kariya et al. 2012) . Additional recent results suggest that the connections between ALS, SMA and the processes that occur in nuclear bodies may actually extend further. One peculiar point of contact is linked to the 3 0 -end processing of histone mRNAs.
New roles for the proteins together: a tale of histones and DNA
In spite of being transcribed by RNA Pol II, replicationdependent histone mRNAs lack a poly-A tail and present a unique 3 0 -end structure that requires specific processing and transcription termination events (Marzluff et al. 2008) . Histone mRNA 3 0 end processing requires the U7snRNP and seems to occur in association with nuclear bodies, either CBs or HLBs, which assemble near histone gene clusters (Frey and Matera 1995) . As could be predicted from SMN's role as a chaperone for snRNP assembly, Tisdale and colleagues recently reported that low levels of SMN affect U7snRNP biogenesis and, in consequence, histone mRNA processing (Tisdale et al. 2013) . This observation led to the suggestion that defects in histone biogenesis could contribute to the etiology of SMA. This hypothesis could provide an explanation for the increased susceptibility of SMA patient fibroblasts to genotoxic stress (Tisdale et al. 2013) . In a recent twist to this story, Raczynska et al. reported that FUS is also involved in histone mRNA biogenesis. FUS interacts with the U7snRNP and the histone transcriptional coactivator NPAT, leading both to increased transcription and processing of histone mRNAs (Raczynska et al. 2015) . Thus, FUS and SMN seem to be connected to the processing of these mRNAs in a context that likely involves CBs and their associated structures (Fig. 3) .
CBs have been linked to several additional cellular functions, including telomere maintenance and the cellular response to stress (Machyna et al. 2013) , two functions that have also been reported for FUS (reviewed by Sama et al. 2014) . The recruitment of FUS to sites of DNA damage was recently shown to be dependent on the CB component PARP1 (Rulten et al. 2014 ). PARP1, a well known regulator of the DNA damage response (Schreiber et al. 2006) , is required for the assembly and maintenance of CBs and was proposed to act by assisting the shuttling of proteins from CBs to chromatin and back (Kotova et al. 2009) .
It is noteworthy that CBs respond to many cellular stimuli, including DNA damage, by changing their number and structure. A recent and intriguing publication suggests that CBs may orchestrate the genome-wide clustering of snRNA, histone, spliceosome, and DNA damage repair-related genes (Wang et al. 2016) . CBs were thus proposed to function as genome organizing centers with a widespread influence on DNA and RNA metabolism (Wang et al. 2016) . The presence of many ALS-and SMA-related proteins within CBs and in their associated compartments gems and HLBs thus suggests an intriguing connection between MND, genome homeostasis, and RNA metabolism.
Common association with small nuclear ribonucleoproteins
The reported disruption of gems observed in cells with mutant TDP-43 and FUS suggested that snRNP biogenesis could also be affected in ALS. In fact, reduction in TDP-43 was shown to cause a down-regulation of SMN and gemins, together with alterations in snRNP abundance (Ishihara et al. 2013; Tsuiji et al. 2013) . The changes in snRNP abundance are, however, distinct from those found in SMA cells. In fact, although reported results vary with cell type, the abundance of several UsnRNAs seems predominantly to increase in cells with low levels or mutant TDP-43 (Ishihara et al. 2013; Tsuiji et al. 2013) . Notably, this increase in snRNA levels is coupled to their subcellular mislocalization, which could be consistent with a functional reduction in snRNP availability (Tsuiji et al. 2013 ). Thus, the functional impact of abnormal TDP-43 function on snRNP dependent activities may turn out to be similar to the one observed in SMA cells.
Similar to TDP-43, FUS was also shown to interfere with the cellular availability of snRNPs (Gerbino et al. 2013; Sun et al. 2015) . Analysis of fibroblasts derived from ALS patients revealed a mutation-dependent impact of FUS on snRNA levels (Sun et al. 2015) . Thus, the H517Q substitution and the frameshift mutation M511Nfs*6 resulted in a reduction in snRNA levels. In contrast, the R521G substitution, also localized in the NLS domain, resulted in an increased abundance of several major class snRNAs, accompanied by the down-regulation of minor class snRNAs U4atac and U6atac. Mouse spinal cord MNs revealed yet another distinct profile, with significant reduction in the levels of the U1 and U11 snRNAs (Sun et al. 2015) . These results are reminiscent of the cell-type-dependent effects observed for TDP-43 mutations, while confirming that both proteins interfere with snRNP biogenesis. This fact brings the impact of ALS-causing mutations in FUS and TDP-43 closer to the SMA phenotype. It remains presently unclear whether common signatures indicative of a general perturbation of the snRNP machinery can be found in both diseases.
Analysis of the FUS interactome identified the U1 snRNP as one of its main binding partners, in addition to SMN (Yamazaki et al. 2012; Sun et al. 2015) . Components of the U1snRNP Sm core particle were found to be mislocalized in cells expressing the ALS-causing R495X mutation in the FUS NLS. Moreover, and U1snRNP knockdowns in different models resulted in similar phenotypes observed to be induced by FUS mutations, exposing a strong functional connection between the two (Gerbino et al. 2013; Yu and Reed 2015) . Notably, U1 snRNPs are known to be involved in additional, non-spliceosomal functions (West 2012) . In agreement with this, their cellular abundance is estimated to be 2-4 fold higher than that of other UsnRNPs (Baserga and Steitz 1993) . This imbalance was recently shown to be achieved thanks to an alternative assembly pathway in which the U1snRNA is directly presented to the SMN-Gemin2 complex by the U1-70K protein rather than Gemin 5 (So et al. 2016) . This recent study opens the possibility that multiple RBPs may act to present different RNA molecules to the SMN-Gemin2 complex, which could thus function more broadly as an RNP-exchanger, facilitating the assembly of RNPs from multiple donors and acceptors.
The first evidence for additional cellular functions for the U1snRNP came from the elucidation of the mechanism by which the presence of an intron near the transcription start site (TSS) leads to an increase in transcription initiation . The presence of a promotor-proximal 5 0 splice site allows the U1 snRNP and TFIIH transcription factors to interact, enhancing the formation of the first nucleotide bond after initiation (Kwek et al. 2002) . Alternative U1 snRNP complexes involving the transcriptional regulator TAF15 have also been reported (Jobert et al. 2009 ). In agreement with a splicing-independent function in gene expression, U1snRNP is the only UsnRNP found to associate with the loci of intronless genes (Spiluttini et al. 2010) .
The functional versatility of U1snRNP extends well beyond transcriptional initiation. Binding of this complex to pre-mRNAs has been known for a long time to inhibit the use of poly-A signals (Gunderson et al. 1998) . The relevance of this inhibitory interaction is actually manifold. First, it was shown to be essential to support transcription across long introns (Alexander et al. 2010; Kaida et al. 2010) . poly-A signals are very frequent in intronic sequences and binding of U1snRNP prevents premature cleavage of the pre-mRNA by suppressing their recognition. Second, reduction in U1snRNP abundance under specific cellular conditions can result in a regulatory switch promoting the selection of upstream poly-A sites, thus leading to a shortening of 3 0 UTR sequences . Interestingly, this phenomenon seems to be particularly important in neuronal activation. Finally, the interaction between poly-A signals and U1snRNP-binding sites was shown to have a critical role in regulating transcription directionality (Almada et al. 2013) . Genome-wide analysis of mammalian gene expression has revealed that transcription initiates bi-directionally at CpG promotors. The absence or presence of U1-binding sites on each side of the promotor establishes the distinction between the productive and non-productive direction of transcription. This ensures the quick cleavage and degradation of one of the products, while the other remains protected.
Thus, the U1snRNP seems to be a critical element for proper transcriptional balance across the whole genome.
Considering the interactions between SMN, FUS and the U1snRNP described above, this new perspective on the function of U1snRNP points to a potential role for altered transcription initiation and termination in SMA and ALS. In agreement with this, FUS was recently shown to influence mRNA length in a way very similar to the U1snRNP, again with the authors proposing a preponderant role for this regulatory mechanism in neuronal gene expression (Masuda et al. 2015) . This observation was further expanded by a report from the Reed lab showing that FUS is required to mediate interactions between RNA Pol II and the U1snRNP (Yu and Reed 2015) . Thus, U1snRNP splicing-independent functions may contribute to changes in transcription control critical for motor neuron degeneration. Just as an unexpected twist in the plot, the recent identification of a novel critical role for SMN and Senataxin in Pol II transcription termination further extends this perspective and provides an exciting new connection between ALS and SMA.
New components in the transcription molecular machinery
Transcription by Pol II has been known for a long time to be highly interconnected to RNA processing events. This occurs in large part through a complex signaling and docking platform provided by the Pol II C-terminal domain (CTD) (reviewed by Bentley 2014). These connections extend from all steps of transcription (initiation, elongation, and termination) down to events required for the formation of a mature mRNA, including the packaging of the molecule into an mRNP-export competent complex. The association of the nascent RNA molecule to RBPs occurs as soon as it emerges from the Pol II complex, with the CTD ensuring the immediate local availability of the appropriate proteins. This is achieved through the dynamic modulation of CTD-protein interactions by an elaborate flow of post-transcriptional modifications that reflect the ongoing transcription stage (Bentley 2014) . The association of RBPs with RNA has additionally been shown to be critically important to avoid the invasion of the template DNA-strand by the nascent transcript. This would lead to the formation of DNA/RNA hybrid structures known as R-loops (reviewed by SantosPereira and Aguilera 2015). Uncontrolled R-loop formation occurs mostly over G-rich regions potentially leading to increased DNA damage and genome instability (SantosPereira and Aguilera 2015). However, recent results have shown that R-loops have a critical function at the end of many mammalian genes, by inducing Pol II pausing and supporting transcription termination (Skourti-Stathaki et al. 2011) .
Although the 3 0 ends of mRNA molecules are formed by cleavage at poly-A sites, Pol II transcription continues beyond this point until the enzyme is derailed by the 5 0 -to-3 0 Xrn2 exonuclease (reviewed by Porrua and Libri 2015) . Xrn2 latches on to the free, uncapped 5 0 end of the cleaved RNA transcript, degrading it and leading to Pol II termination. This process is facilitated by Pol II pausing at G-rich regions downstream of the Poly-A site. Interestingly, Pol II pausing was shown to occur as a result of R-loop formation, in the absence of which transcription will continue, leading to read-through intergenic products (Skourti-Stathaki et al. 2011) . Proper transcription termination further requires the resolution of these R-loops, allowing Xrn2 to access the RNA transcript. This was shown to be performed by Senataxin (Skourti-Stathaki et al. 2011) , thus explaining the previous observations that implicated this protein in the termination of transcription (Suraweera et al. 2009 ). The recent publication of Zhao and colleagues sheds further light onto this story by identifying SMN as the intermediary that connects Senataxin to the Pol II CTD (Zhao et al. 2016) . SMN, already known to functionally interact with the Pol II CTD (Pellizzoni et al. 2001) , turns out to bind specifically to the di-methylated form of the arginine residue (R1810) in Pol II, recruiting Senataxin to elongating complexes. Knockdown of SMN or Senataxin results in global changes in the association of Pol II to chromatin, which accumulates in the termination region of active genes (Zhao et al. 2016) . This occurs in parallel with the accumulation of R-loops at the end of genes, affecting the efficiency of termination. Reduced transcription initiation was also reported in these knockdown experiments, which may be linked to the observation that R-loops are also found at the promotor region, immediately after the TSS (Ginno et al. 2012) . Interestingly, mutation of the Pol II CTD R1810 to an alanine prevents its methylation and was found to specifically result in altered snRNA expression in human cells (Zhao et al. 2016) .
The relevance of R-loops in the context of ALS had already been proposed and discussed by several authors, with particular emphasis on the connections to genome stability and genotoxic stress (Salvi and Mekhail 2015) . Zhao and coworkers recent report reveals that SMA patient-derived cells display similar phenotypes to the ones observed in Senataxin knock-down cells, as would be expected from this new SMN function (Zhao et al. 2016) . These results provide novel insights regarding the mechanisms underlying motor neuron degeneration in SMA and ALS4, highlighting unsuspected connections between the two diseases. Furthermore, they significantly expand a model of highly inter-twined regulation of RNA synthesis and genome homeostasis involving transient interactions and complexes formed between TDP-43, FUS, Senataxin and SMN. Although not discussed in this review, these connections clearly extend to cytoplasmic functions through the control of axonal RNA-trafficking, translation and the formation of structures like RNA stress-granules (see, for example, Fallini et al. 2012a,b; Alami et al. 2014; Groen et al. 2013) . It is likely that such functions also play an important role in the motor neuron-specific effects of diseasecausing mutations in these proteins.
Enter omics: genomic and transcriptomic data analysis to reveal new links
The recent insights on the functional interactions between FUS, TDP-43, SMN and Senataxin strongly suggest the existence of common pathway(s) for motor neuron degeneration connected to RNA-transcriptome homeostasis. To date, the reason for the cell type specificity of the ALS/SMA phenotype remains elusive. In particular, whether there are specific genes with altered expression leading to MND or whether motor neurons are responding with high sensitivity to a disruption in transcriptome homeostasis, coupled to alterations in cytoplasmic functions, is presently unclear. We propose that a comparative study of the transcriptome changes present in different cell types with SMN, TDP-43, FUS, and Senataxin disease-causing mutations may assist in the identification of common disease pathways and thus contribute to unravel the specific mechanisms underlying motor neuron death. Several public datasets from human patient tissues and cells, as well as from mouse and rat models of these diseases, are currently available (Table 2) . These data provide a starting point for an integrative approach to ALS and SMA, which could at the same time explore the relevance of the links that have recently emerged. Analysis of genomic data is strongly influenced by the computational algorithms, which may be more suited to address certain expected changes in detriment to others. For example, most approaches aimed at quantifying gene or splicing isoform levels will not be efficient at assessing altered transcription termination. In addition, meta-analysis studies of different mutant backgrounds and the integration of results focusing on different approaches -that is, chromatin association versus transcript levels -has not been pursued in many cases. Thus, the reanalysis of these datasets in light of the emerging new connections between ALS and SMA may provide interesting insights into the mechanisms underlying motor neuron degeneration. Considering the existence of several animal models that mimic both the SMA and ALS motor neuron degeneration phenotype, the possibility of comparing cross-species data may provide an additional guide to the identification of common critical pathways. However, studies using matched tissues and conditions for all mutations are lacking and would provide a critical contribution for the implementation of this kind of cross-disease approach.
Conclusions: ALS and SMA diseases disrupt RNAtranscriptome homeostasis
The identification of disease-causing mutations and the downstream molecular mechanisms that link ALS and SMA to the ensuing phenotype can provide the basis for the development of effective therapeutic approaches. However, moving from the disease-causing gene to mechanism can be quite a challenging task, in particular in contexts were the mutation of an ubiquitously expressed protein leads to cell type specific phenotypes, as is the case with SMA and ALS. Accordingly, more than one decade after the identification of the underlying disease-associated genes, we are still far from understanding how their encoded proteins are connected to motor neuron death.
During the last few years, several lines of evidence have suggested the existence of shared molecular pathways between ALS and SMA. These come from genetic studies reporting the association between aberrant SMN copy numbers and ALS predisposition, to an increasing number of reported interactions between disease-causing genes. In spite of evident commonalities, these diseases have been traditionally studied separately, probably because of the specificity of the clinical manifestations of their most frequent forms. The fact that SMA usually appears as an early childhood hereditary disorder, while ALS presents as a late onset, progressive adult neurodegeneration, most frequently of sporadic nature, has probably been the main driving force in this divide. We propose that the most recent evidence connecting two of the ALS and the SMA disease-causing genes supports the hypothesis of common critical pathways linked to RNAtranscriptome homeostasis underlying motor neuron degeneration in these diseases. Comparative studies, in particular those using high-throughput approaches, may provide the focus required for their identification.
